Biocon, DKSH ink pact to commercialize 7 generic formulations in Singapore, Thailand

This development is in line with Biocon's strategy for the expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.

Siddharth Mittal, CEO & Managing Director, Biocon, said: "We are happy to partner with DKSH to commercialize Biocon's generic formulations pipeline in key South East Asian markets of Singapore and Thailand. This collaboration will enable us to address the growing patient needs for affordable access to high-quality generics for chronic diseases and expand our commercial footprint in this region. Our generic formulations pipeline comprises of difficult-to-make, complex molecules and leverages our strong track record of quality and reliability of supplies to our patients and customers."

Bijay Singh, Global Head of Business Unit Healthcare, DKSH, said: "DKSH helps Asian patients get reliable and efficient access to the best healthcare possible, with an emphasis on quality and compliance, leveraging technology wherever possible. Together with Biocon Pharma, we can help a lot of patients in Asia who require advanced therapies for chronic diseases. We are delighted to provide full agency services to Biocon Pharma. We will manage marketing and sales as well as logistics for Biocon's products in several therapeutic areas, such as cardiology, diabetes, immunology, and oncology in Singapore and Thailand. With a broad reach across our medical channel in Asia, we are committed to driving growth for Biocon Pharma and improving access to healthcare products for all."

Read also: Biocon, Mylan get USFDA approval for insulin glargine injection Semglee